HALIFAX, Aug. 10 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, announced today the introduction of new Multiplo(TM) rapid tests at
the US Military's Advanced Technology Applications for Casualty Combat Care
(ATACCC) Conference taking place this week in St. Pete's Beach, FL.
MedMira is launching several new combination rapid tests for infectious
and tropical diseases, and sexually transmitted diseases at the ATACCC
Conference. Specifically these new tests will be used to diagnose disease such
as HIV, Hepatitis B and C, syphilis, malaria, and Dengue fever in various
combinations. The expanded Multiplo(TM) line also includes monitoring
capabilities for vaccination effectiveness, applicable in military
pre-deployment screening, public health vaccination programs, and vaccine
Employing MedMira's distinctive and patented rapid flow-through
technology, many of these new Multiplo(TM) tests will be the first of their
kind in the diagnostics industry. The technology's unique advantages are
multiple instant results on one test cartridge as well as the ease with which
new test combinations can be geared up for full commercialization.
"Introducing our latest Multiplo(TM) diagnostic combinations at the
ATACCC Conference is a good opportunity to clearly demonstrate the unique
advantages and diversity of applications that our rapid diagnostic technology
can offer to military medicine as well as civilian healthcare," said Hermes
Chan, CEO, MedMira Inc. "There are some exceptional challenges in military
medicine and we believe that our rapid diagnostics and technology can be very
beneficial, bringing increased efficiency and improving patient outcomes."
The ATACCC brings together over 1,200 scientists and medical personnel
and is the Department of Defense's (DOD) premier scientific meeting that
focuses on the battlefield medical needs of warfighters and on recent advances
in trauma surgery and medicine.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information:
For further information: MedMira Contact: Andrea Young, (902) 450-1588,